Since STAT3, NFκB, and PPARγ are closely related to the pathology of NASH and liver fibrosis, we hypothesized that XYS may exert antifibrotic effects through these three TFs. This evidence concerns the gene STAT3 and metabolic dysfunction-associated steatohepatitis.